Arcus Biosciences (RCUS) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mail
Get Alerts RCUS Hot Sheet
Join SI Premium – FREE
Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.27), $0.01 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $26 million versus the consensus estimate of $24.57 million.
For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ONEOK (OKE) Tops Q3 EPS by 63c; raises guidance
- OrthoPediatrics (KIDS) Reports In-Line Q3 EPS
- First Carolina Financial Services, Inc. (FCBM) Reports Q3 EPS of $0.26
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
